<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04003350</url>
  </required_header>
  <id_info>
    <org_study_id>2019MAUSTKA</org_study_id>
    <nct_id>NCT04003350</nct_id>
  </id_info>
  <brief_title>The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee Arthroplasty</brief_title>
  <official_title>The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rothman Institute Orthopaedics</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rothman Institute Orthopaedics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is well recognized that a multimodal analgesia program targeting multiple pain pathways,
      is more effective for controlling pain during the hospital stay and in the acute
      postoperative period than monotherapy-based regimens, such as opioids only. This multimodal
      analgesic regimen also leads to reduce opioid consumption and its related side effects after
      hip and knee joint replacement procedures. One potential strategy to reduce the use of
      opioids after TKA is to administer a prolonged oral multimodal pain regimen that targets
      multiple pain pathways in the post hospital discharge period. This can be equal or more
      effective than the regimen of opioid prescriptions used after TKA. To the best of our
      knowledge, there have been no studies conducted that directly examine the effect of prolonged
      multimodal pain regimen after hospital discharge in primary TKA patients.

      PURPOSE:

        1. To determine whether a prolonged multimodal pain regimen after discharge from primary
           TKA can provide equivalent or better pain control while reducing opioid consumption and,
           subsequently, opioid-related side effects.

        2. To determine whether patient expectations and routine opioid prescription practices at
           the time of discharge from primary TKA impacts opioid consumption.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 21, 2017</start_date>
  <completion_date type="Actual">March 15, 2019</completion_date>
  <primary_completion_date type="Actual">November 26, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative pain</measure>
    <time_frame>Postsurgery days 1-30</time_frame>
    <description>Measured via Visual Analog scale (0-100mm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid related side effects</measure>
    <time_frame>post-surgery days 1-30</time_frame>
    <description>Severity measured via Visual Analog scale (0-100mm)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>opioid consumption</measure>
    <time_frame>post-surgery weeks 1-4</time_frame>
    <description>morphine milligram equivalent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>opioid consumption</measure>
    <time_frame>post-surgery weeks 1-4</time_frame>
    <description>number of pills consumed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of opioid refills</measure>
    <time_frame>post-surgery weeks 1-4</time_frame>
    <description>number of times subjects asked to have an opioid prescription refilled during post-operative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90 day complications</measure>
    <time_frame>post-surgery 90 days</time_frame>
    <description>collection of all post-operative medical complications within the first 90 days after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Osteo Arthritis Knee</condition>
  <arm_group>
    <arm_group_label>Opioid Regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weeks 1-4
Oxycodone 5 mg PRN q4h (30 tablets)
Tramadol 50 mg PRN q6h (30 tablets)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multimodal pain regimen with PRN opioids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weeks 1-4
Tylenol 1000 mg q8h (standing)
Meloxicam 15 mg qD (standing).
Gabapentin 200 mg BID (with morning and evening Tylenol dose)
Metaxalone 800mg PO TID (Tizanidine 2mg q8h if insurance coverage is not possible for metaxalone)
Esomeprazole 20mg daily if not already on another H2 blocker or PPI
Oxycodone 5 mg PRN q4h (30 tablets)
Tramadol 50 mg PRN q6h (30 tablets)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>Patients are given, for up to 4 weeks, Oxycodone 5m PRN every four hours (up to 30 tablets)</description>
    <arm_group_label>Multimodal pain regimen with PRN opioids</arm_group_label>
    <arm_group_label>Opioid Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>Patients are given, for up to 4 weeks, Tramadol 50mg PRN every 6 hours (up to 30 tablets)</description>
    <arm_group_label>Multimodal pain regimen with PRN opioids</arm_group_label>
    <arm_group_label>Opioid Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tylenol</intervention_name>
    <description>Tylenol 1000 mg: take as needed every 8 hours</description>
    <arm_group_label>Multimodal pain regimen with PRN opioids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam</intervention_name>
    <description>Meloxicam 15 mg as need once per day</description>
    <arm_group_label>Multimodal pain regimen with PRN opioids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>â€¢Gabapentin 200 mg with morning and evening Tylenol dose</description>
    <arm_group_label>Multimodal pain regimen with PRN opioids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metaxalone</intervention_name>
    <description>Metaxalone 800mg TID</description>
    <arm_group_label>Multimodal pain regimen with PRN opioids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 20mg</intervention_name>
    <description>Esomeprazole 20mg daily</description>
    <arm_group_label>Multimodal pain regimen with PRN opioids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing unilateral primary TKA with underlying diagnosis of
             osteoarthritis.

          -  ASA I - III

          -  Spinal anesthesia

          -  All patients will have cemented total knee utilizing a medial parapatellar approach
             including patellar resurfacing. A tourniquet will be used in all cases

          -  Male and Female over 18 who are willing and able to provide informed consent

        Exclusion Criteria:

          -  Opioid use within 3 months preoperatively

          -  Inability to take the protocol medications

          -  Anticoagulant other than aspirin

          -  Contraindication to regional anesthesia

          -  Non-english speaking

          -  ASA IV or greater

          -  Psychiatric or cognitive disorders

          -  Allergy/contraindications to protocol medications.

          -  Renal insufficiency with Cr &gt; 2.0 or hepatic failure

          -  General anesthesia

          -  Sensory/motor disorder involving the operative limb
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rothman Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2019</study_first_posted>
  <last_update_submitted>June 27, 2019</last_update_submitted>
  <last_update_submitted_qc>June 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Meloxicam</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Metaxalone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

